Last reviewed · How we verify
MMRV (2006 process)
MMRV is a live attenuated combination vaccine that provides immunization against measles, mumps, rubella, and varicella by stimulating immune responses to all four viruses.
MMRV is a live attenuated combination vaccine that provides immunization against measles, mumps, rubella, and varicella by stimulating immune responses to all four viruses. Used for Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older.
At a glance
| Generic name | MMRV (2006 process) |
|---|---|
| Also known as | ProQuad™ |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Live attenuated combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
MMRV combines the Merck MMRII (measles, mumps, rubella) vaccine with the Varivax (varicella) vaccine into a single formulation. Each component contains live attenuated virus strains that replicate in vaccinated individuals, triggering both humoral and cellular immune responses without causing disease. This provides protection against all four viral infections with a single injection.
Approved indications
- Prevention of measles, mumps, rubella, and varicella in children aged 12 months and older
Common side effects
- Injection site reactions (erythema, swelling, tenderness)
- Fever
- Rash
- Varicella-like rash at injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMRV (2006 process) CI brief — competitive landscape report
- MMRV (2006 process) updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI